MedTrace Logo

N-Acetylcysteine as an Adjuvant Therapy in Critically Ill COVID-19 Patients:

NCT05504655 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2023-02-06

No results posted yet for this study

Summary

In this study, we retrospectively will investigate safety and efficacy of NAC dose given in paracetamol toxicity as an adjuvant therapy in critically ill COVID-19 patients with acute respiratory distress and determine whether NAC in high doses can avoid respiratory failure in patients with COVID-19.

Conditions

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2022-11-27
Completion
2022-12-22

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05504655 on ClinicalTrials.gov